Unique ID issued by UMIN | UMIN000005186 |
---|---|
Receipt number | R000006144 |
Scientific Title | A randomized, double-blind, placebo-controlled, crossover trial of D-cycloserine in schizophrenic patients |
Date of disclosure of the study information | 2011/03/03 |
Last modified on | 2011/08/12 10:18:06 |
A randomized, double-blind, placebo-controlled, crossover trial of D-cycloserine in schizophrenic patients
A double-blind, placebo-controlled, crossover trial of D-cycloserine in schizophrenic patients
A randomized, double-blind, placebo-controlled, crossover trial of D-cycloserine in schizophrenic patients
A double-blind, placebo-controlled, crossover trial of D-cycloserine in schizophrenic patients
Japan |
Schizophrenia
Psychiatry |
Others
NO
To examine the effects of facilitation of the NMDA type glutamate receptor function by D-cycloserine on the antipsychotic-resistant symptoms of schizophrenia, we will conduct the clinical study that the schizophrenic patients treated with the ordinary antipsychotic drugs will participated in a double-blind, placebo-controlled, crossover trial of 50 mg/day D-cycloserine added to their medication. The clinical efficacy will be compared 1) between the patients treated with placebo and those with D-cycloserine, and 2) between the placebo-treated period and the D-cycloserine-treated period in the individual patients.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
1) PANSS:Changes in total scores
2) SANS:Changes in total scores
1) PANSS:Changes in total scores
2) PANSS:Total scores
3) PANSS:Changes in subscale scores
4) SANS:Changes in total scores
5) SANS:Total scores
6) SANS:Changes in subscale scores
7) GAS:Scores of the Global Assessment Scale
8) JCDSS:Scores of the Japanese version of the Calgary Depression Scale for Schizophrenia
9) DIEPSS:Scores of the Drug-Induced Extra-Pyramidal Symptoms Scale
10) Edinburgh inventory
11) AIMS:Scores of the Abnormal Involuntary Movement Scale
12) EQS:Scores of the Emotional Intelligence Scale
13) BACS:Scores of the Brief Assessment of Cognition in Schizophrenia
14) MCCB-J:Scores of the Japanese version of the MATRICS Consensus Cognitive Battery
15) The serum levels of D-cycloserine
16) The serum levels of D-serine
17) Brain MRI
18) Brain MR spectroscopy
19) The pattern of changes in NIRS signals during frontal cortex activation
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
NO
Institution is considered as a block.
NO
Central registration
2
Treatment
Medicine |
D-cycloserine 25mg x 2/day
placebo
20 | years-old | <= |
70 | years-old | >= |
Male and Female
Subjects are all inpatients who fulfilled the following inclusion criteria:
1)DSM-IV (American Psychiatric Association 1994) diagnosis of schizophrenia;
2) 20-70 years old;
3) men and women;
4) outpatients and inpatients;
5) written informed consent is obtained from patients themselves after the description and explanations of the study to them orally and in writing.
Patients who meet the following criteria should be excluded:
1) under being treated with the structured psychotherapies or cognitive-behavioral therapies within 12 weeks before the beginning of this study;
2) DSM-IV diagnosis of substance-related disorders within 24 weeks before the beginning of this study;
3) under being treated with the electroconvulsive therapy within 12 weeks before the beginning of this study;
4) during pregnancy and lactation or the possible pregnancy within 30 days after the end of this study;
5) suicide attempt within 24 weeks before the beginning of this study;
6) history or complication of convulsive disorders;
7) history of hypersensitivity to D-cycloserine or lactose;
8) complication of serious organic brain diseases;
9) complication of serious somatic disorders including hepatopathy, nephropathy, cardiopathy, etc.;
10) implantation of metal materials in the body;
11) insertion of a cardiac pacemaker;
12) under being treated with D-cycloserine;
13) other conditions that are considered to be inappropriate to the present trial by its investigators.
30
1st name | |
Middle name | |
Last name | Tetsuro Ohmori |
Tokushima University Hospital
Psychiatry
2-50-1, Kuramoto-cho, Tokushima 770-8503, Japan
088-633-7130
1st name | |
Middle name | |
Last name | Tetsuro Ohmori |
Tokushima University Hospital
Psychiatry
2-50-1, Kuramoto-cho, Tokushima 770-8503, Japan
088-633-7130
Tokyo Medical and Dental University
Ministry of Education, Science and Culture, Japan/Tokyo Medical and Dental University
NO
徳島大学病院(徳島県)
2011 | Year | 03 | Month | 03 | Day |
Unpublished
Enrolling by invitation
2011 | Year | 02 | Month | 15 | Day |
2011 | Year | 04 | Month | 01 | Day |
2015 | Year | 03 | Month | 01 | Day |
2011 | Year | 03 | Month | 03 | Day |
2011 | Year | 08 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006144
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |